Recently in 2021, two ileal bile acid transporter (IBAT) inhibitors, maralixibat and odevixibat, have been approved for the treatment of pruritus in patients with Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis (PFIC), respectively, and showed efficacy in reducing the intrahepatic retention of bile acids (Miethke et al, 2024; Ovchinsky et al, 2024). Here, SLC10A2 is linked to Alagille syndrome.